WHY IT MATTERS: Patients and caregivers exploring cannabinoid options for neurological conditions should understand that while the basic science is genuinely promising, the gap between preclinical findings and proven clinical treatments means these approaches are best pursued under informed medical guidance rather than based on headlines alone. CLINICAL OVERVIEW: The endocannabinoid system plays a fundamental role in regulating neuronal health, modulating inflammation, oxidative stress, and cell survival pathways that are central to neurodegenerative disease processes. Non-psychoactive cannabinoids such as CBD, CBG, and CBDV interact with receptors and signaling cascades throughout the central nervous system in ways that may slow or interrupt the progression of conditions like Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury sequelae.
Study finds no links between cannabis use and cognitive decline or dementia in older people
WHY IT MATTERS: Older adults who use cannabis for pain, sleep, or anxiety can share this research with their physicians to support more informed, evidence-based conversations about risk rather than assumption-based discouragement. CLINICAL OVERVIEW: Concerns about cannabis use accelerating cognitive decline or contributing to dementia risk in older adults have long influenced clinical conversations, but emerging research is beginning to challenge those assumptions. The biological reality is complex, given that the endocannabinoid system plays a regulatory role in neuroinflammation and neuroprotection, and that older adults are using cannabis for legitimate symptom management at increasing rates.